My Treatment Approach: Improving Chronic Lymphocytic Leukemia Management and Treatment Outcomes - Episode 13

Management Strategies for BTKi-Related CVAEs in CLL

, ,

Bita Fakhri, MD, MPH, shares her general approach to managing common cardiovascular adverse events associated with BTK inhibitors in patients with chronic lymphocytic leukemia.

EP. 1: Patient with Newly Diagnosed CLL with High-Risk Features
EP. 2: Expert Perspectives on 1L Treatment Approaches in Newly Diagnosed CLL
EP. 3: Navigating Continuous BTKi Therapy for CLL in the 1L Setting
EP. 4: Implications of Real-World Data in the 1L Treatment of High-Risk CLL
EP. 5: Expert Perspectives on Venetoclax-Based 1L Treatment Strategies in CLL
EP. 6: Considerations for 1L Doublet and Triplet Therapy with Venetoclax in CLL
EP. 7: Perspectives on Shared Decision-Making in the Treatment of CLL
EP. 8: Strategies for Optimizing Venetoclax-Based Treatment for Patients with CLL
EP. 9: Expert Insights for Long-Term Treatment Planning in CLL
EP. 10: Patient with R/R CLL Treated with 2L Venetoclax Therapy
EP. 11: Navigating 2L Treatment Options in CLL
EP. 12: Emerging Data with BTKi Resistance: Expert Insights and Treatment Implications
Now Viewing
EP. 13: Management Strategies for BTKi-Related CVAEs in CLL
EP. 14: Updates in CLL Treatment Strategies with Noncovalent BTKis
EP. 15: Looking Ahead: Novel Therapies and Future Perspectives in the Treatment of CLL

Video content above is prompted by the following questions:

  • What is your general approach in managing newly acquired or worsening HTN or treatment-related AFib in patients receiving treatment with BTKi inhibitors?
    • How do you approach treatment management in these clinical scenarios?
    • When do you involve cardiology?
    • When may alternative therapy be warranted?